Compare STE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STE | WAT |
|---|---|---|
| Founded | 1985 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 22.5B |
| IPO Year | 1992 | 1995 |
| Metric | STE | WAT |
|---|---|---|
| Price | $268.33 | $384.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 16 |
| Target Price | $268.25 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 489.5K | 484.9K |
| Earning Date | 02-04-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 59.39 | 3.82 |
| EPS | 6.97 | ★ 10.88 |
| Revenue | ★ $5,702,415,000.00 | $3,105,638,000.00 |
| Revenue This Year | $9.61 | $7.93 |
| Revenue Next Year | $6.23 | $6.30 |
| P/E Ratio | $38.48 | ★ $35.62 |
| Revenue Growth | ★ 7.08 | 6.90 |
| 52 Week Low | $204.90 | $275.05 |
| 52 Week High | $269.44 | $423.56 |
| Indicator | STE | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 65.54 | 47.12 |
| Support Level | $256.51 | $383.07 |
| Resistance Level | $263.08 | $401.74 |
| Average True Range (ATR) | 5.55 | 9.25 |
| MACD | 1.33 | -0.39 |
| Stochastic Oscillator | 95.17 | 35.81 |
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.